TABLE 1

Baseline characteristics of 86 women who enrolled in the PIPOD study and completed at least one follow-up visit

VariableMean (range) ± SD
Age (years)39 (25–54) ± 6.6
BMI (kg/m2)31 (21–48) ± 4.9
Waist-to-hip circumference ratio0.86 (0.72–1.32) ± 0.07
OGTT fasting plasma glucose (mg/dl)*99 (81–124) ± 9.7
OGTT 2-h plasma glucose (mg/dl)*151 (97–199) ± 27.6
OGTT glucose area (mg · dl−1 · min−1 · 10−3)*18.3 (12.0–24.7) ± 2.8
OGTT fasting plasma insulin (μU/ml)*17.4 (5–64) ± 10.4
OGTT insulin area (μU · ml−1 · min−1)*11,058 (3,165–30,120) ± 6,662
A1C (% of hemoglobin)5.7 (4.4–6.6) ± 0.5
Si (min · μU−1 · ml−1 · 10−4)2.33 (0.37–10.90) ± 1.65
AIRg (μU · ml−1 · min−1)408 (−3 to 1,342) ± 292
DI§834 (−2 to 2,418) ± 583
IVGTT insulin area (μU · ml−1 · min−1)9,654 (2,503–36,172) ± 5,743
  • Data are means (range) ± SD.

  • *

    * 75-g OGTT; areas are total calculated by trapezoid rule.

  • Minimal model analysis of IVGTT results.

  • Incremental insulin area during the first 10 min after glucose injection.

  • §

    § Si × AIRg, a measure of β-cell compensation for insulin resistance.

  • Total area from 0 to 240 min. To convert values for glucose to mmol/l, multiply by 0.05551. To convert values for insulin to pmol/l, multiply by 6.0.